Saskatoon hospital foundations offer support to USask’s VIDO
Nov 25, 2021 - Three of Saskatoon’s hospital foundations have partnered to donate $230,000 in support of Canada’s Centre for Pandemic Research at VIDO.
CEPI awards USask’s VIDO $6M for vaccine development
Nov 4, 2021 - VIDO at USask has received approximately CAN$6 million from the Coalition for Epidemic Preparedness Innovations. This is CEPI’s first ever award to a Canadian university.
The University of the Sunshine Coast leads rollout of critical vaccine for koalas
Oct 15, 2021 - USC is leading a Phase 3 rollout of a koala chlamydia vaccine that has been developed collaboratively over many years with many partners, including VIDO.
New funding will help predict SARS-CoV-2 variants and protect vulnerable populations
Oct 4, 2021 - VIDO scientist Dr. Alyson Kelvin was awarded close to half a million dollars to assess COVID-19 vaccine efficacy including against virus variants in vulnerable populations.
Alumni Ron and Jane Graham’s $5.9M gift assists vaccine research, Huskie Athletics, engineering and education students at USask
Sep 17, 2021 - The University of Saskatchewan’s most generous alumni, Ron and Jane Graham, are supporting the Vaccine and Infectious Disease Organization with a $1M donation.
Three USask researchers become fellows in the Canadian Academy of Health Sciences
Sep 14, 2021 - Dr. Volker Gerdts, VIDO Director and CEO, has been inducted as fellows to the Canadian Academy of Health Sciences.
Saskatoon couple donates $1 million to VIDO to enhance ground-breaking vaccine research
Aug 27, 2021 - Malcolm and Marilyn Leggett have donated $1 million to help establish VIDO as Canada’s Centre for Pandemic Research and advance its ground-breaking research on infectious diseases, including COVID-19.
Infectious disease research bolstered by Hospitals of Regina Foundation
Jul 20, 2021 - To help protect Saskatchewan residents from emerging disease threats, Hospitals of Regina Foundation has invested $150,000 to help establish Canada’s Centre for Pandemic Research at USask's Vaccine and Infectious Disease Organization.
VIDO research provides insight into the immune response and possible long-term health impacts associated with COVID-19
Jul 15, 2021 - One of the newest scientists at the University of Saskatchewan’s Vaccine and Infectious Disease Organization has published new research on potential lasting effects of COVID-19.
USask’s VIDO announces positive Phase 1 results for COVAC-2
Jun 23, 2021 - The Vaccine and Infectious Disease Organization at the University of Saskatchewan announced positive interim results from their Phase 1 clinical trial for COVAC-2, VIDO’s COVID-19 subunit vaccine candidate.
Sask.-based research offers hope in unsettling times
Jun 7, 2021 - Uncertain times require robust social sciences and humanities analysis, and leadership from scholars to discuss complex issues with the public.
Saskatchewan Blue Cross invests $150K to help establish USask’s VIDO as Canada’s Centre for Pandemic Research
May 19, 2021 - The Vaccine and Infectious Disease Organization at the University of Saskatchewan is one step closer to establishing its Centre for Pandemic Research, thanks to a $150,000 donation from Saskatchewan Blue Cross.
Ministers Champagne, Joly and Carr highlight Budget 2021 biomanufacturing investments
Apr 23, 2021 - Budget 2021 proposes to provide $59.2M to USask's VIDO, through Western Economic Diversification Canada’s Regional Economic Growth through Innovation program, to help it develop and manufacture bio-solutions such as vaccines and therapeutics.
Federal budget supports USask’s VIDO with $59.2M
Apr 19, 2021 - Today the Government of Canada announced $59.2 million to VIDO to support the development of its vaccine candidates and the expansion of its research facilities, including a National Centre for Pandemic Research.
USask researchers seek to prevent liver disease, high blood pressure, and understand lifelong impacts of Zika virus
Mar 23, 2021 - Three University of Saskatchewan researchers have been awarded a total of $1.87 million by the Canadian Institutes for Health Research (CIHR) for projects involving fatty liver disease, high blood pressure, and Zika virus.
Canada’s Global Nexus and VIDO join forces to combat COVID–19
Feb 25, 2021 - Canada’s Global Nexus for Pandemics and Biological Threats at McMaster University and VIDO at USask are working together to accelerate vaccine and drug development, human clinical trials and create new diagnostic tools.
VIDO gains provincial support towards becoming a ‘Centre for Pandemic Research’
Feb 23, 2021 - The Government of Saskatchewan committed $15 million to support the University of Saskatchewan’s Vaccine and Infectious Disease Organization’s position as a Centre for Pandemic Research.
USask’s VIDO begins COVID-19 vaccine clinical trials at CCfV
Feb 3, 2021 - The first volunteers have been selected for a vaccine trial of COVAC-2, a COVID-19 vaccine developed by the Vaccine and infectious Disease Organization at the University of Saskatchewan.
New support to produce COVID-19 vaccines and treatments in Canada
Feb 2, 2021 - Prime Minister Justin Trudeau's announcement regarding new support to produce #COVID19 vaccines and treatments in Canada:
USask livestock research receives significant investment to advance industry
Jan 27, 2021 - Saskatchewan’s Agriculture Development Fund will provide more than $6.5 million to support livestock research efforts at USask including $1.58 million for VIDO.
A new year, and a new look
Jan 18, 2021 - With a refreshed recognition of our history and in celebration of our future, we recently embraced a new, enhanced visual identity that symbolizes our national and international impact.